ZIOP insider filings
ZIOPHARM ONCOLOGY INC — 27 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-12-27. Screen ZIOP transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ZIOP between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — ZIOPHARM ONCOLOGY INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2021-12-27 | 4 | De Groot Eleanor — EVP, Operations | Sale (S): 20,132 @ $1.27 | EDGAR |
| 2021-12-13 | 4 | Lackey Melinda — Senior Vice President, Legal | Grant/award (A): 370,000 (derivative) @ $0 | EDGAR |
| 2021-11-17 | 4 | Boyle Kevin S. Sr. — Chief Executive Officer, Director | Purchase (P): 884 @ $1.40 · Purchase (P): 9,116 @ $1.40 | EDGAR |
| 2021-10-04 | 4 | Vieser Jaime — Director | Purchase (P): 100,000 @ $1.91 | EDGAR |
| 2021-09-03 | 4 | Hagen Heidi — Director | Purchase (P): 23,770 @ $1.76 | EDGAR |
| 2021-09-03 | 4 | Weis Holger — Director | Purchase (P): 50,000 @ $1.83 | EDGAR |
| 2021-09-03 | 4 | Postma Robert W — Director | Purchase (P): 20,508 @ $1.73 · Purchase (P): 54,492 @ $1.73 | EDGAR |
| 2021-09-03 | 4 | Huang James — Director | Purchase (P): 100,000 @ $1.71 | EDGAR |
| 2021-08-31 | 4 | Boyle Kevin S. Sr. — Chief Executive Officer, Director | Grant/award (A): 875,000 @ $0 · Grant/award (A): 2,625,000 (derivative) @ $0 | EDGAR |
| 2021-05-19 | 4 | Baffa Raffaele — Chief Medical Officer | Grant/award (A): 80,645 @ $0 | EDGAR |
| 2021-05-06 | 4 | Weis Holger — Director | Grant/award (A): 4,167 @ $0 · Grant/award (A): 31,250 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-05-06 | 4 | Vieser Jaime — Director | Grant/award (A): 4,167 @ $0 · Grant/award (A): 31,250 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-05-06 | 4 | Thistle Mary — Director | Grant/award (A): 5,000 @ $0 · Grant/award (A): 37,500 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-05-06 | 4 | Postma Robert W — Director | Grant/award (A): 2,500 @ $0 · Grant/award (A): 18,750 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-05-06 | 4 | Huang James — Director | Grant/award (A): 8,333 @ $0 · Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2021-05-06 | 4 | BUCHI J KEVIN — Director | Grant/award (A): 4,167 @ $0 · Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2021-05-06 | 4 | Bowden Christopher — Director | Grant/award (A): 4,167 @ $0 · Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2021-03-08 | 4 | Buck Jill — EVP, GM Gene Therapy | Grant/award (A): 31,500 @ $0 · Grant/award (A): 236,250 (derivative) @ $0 | EDGAR |
| 2021-03-08 | 4 | Hadfield Robert — Chief Legal Officer and Sec. | Grant/award (A): 43,500 @ $0 · Grant/award (A): 326,250 (derivative) @ $0 | EDGAR |
| 2021-03-08 | 4 | Hagen Heidi — Interim CEO, Director | Grant/award (A): 90,000 @ $0 · Grant/award (A): 675,000 (derivative) @ $0 | EDGAR |
| 2021-03-08 | 4 | De Groot Eleanor — EVP, GM Cell Therapy | Grant/award (A): 50,825 @ $0 · Grant/award (A): 381,188 (derivative) @ $0 | EDGAR |
| 2021-01-12 | 4 | Buck Jill — EVP, GM Gene Therapy | Sale (S): 27,894 @ $3.12 | EDGAR |
| 2021-01-12 | 4 | Lafond Kevin G — SVP, Treasurer & CAO | Sale (S): 18,020 @ $3.09 | EDGAR |
| 2021-01-12 | 4 | Hadfield Robert — General Counsel and Secretary | Sale (S): 26,500 @ $3.12 | EDGAR |
| 2021-01-06 | 4 | De Groot Eleanor — EVP, GM Cell Therapy | Sale (S): 21,620 @ $2.72 | EDGAR |
| 2021-01-06 | 4 | Cooper Laurence James Neil — President and CEO, Director | Sale (S): 105,693 @ $2.71 | EDGAR |
| 2020-10-13 | 4 | BUCHI J KEVIN — Director | Grant/award (A): 146,190 (derivative) @ $0 | EDGAR |
Recent 8-K events — ZIOPHARM ONCOLOGY INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-23 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-10-21 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-09 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-09-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-17 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | EDGAR |
| 2026-06-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-15 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ZIOP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs